| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre; 2Clinical Integrative Biology, Sunnybrook Research Institute; 3Physiology & Experimental Medicine Program, Hospital for Sick Children Research Institute; and the Departments of 4Anaesthesia, 5Paediatrics, and 6Physiology, University of Toronto, Toronto, Ontario, Canada
Submitted 13 June 2007 ; accepted in final form 20 November 2007
Pulmonary hypertension (PHT) in neonates is often refractory to the current best therapy, inhaled nitric oxide (NO). The utility of a new class of pulmonary vasodilators, Rho-kinase (ROCK) inhibitors, has not been examined in neonatal animals. Our objective was to examine the activity and expression of RhoA/ROCK in normal and injured pulmonary arteries and to determine the short-term pulmonary hemodynamic (assessed by pulse wave Doppler) effects of ROCK inhibitors (15 mg/kg ip Y-27632 or 30 mg/kg ip fasudil) in two neonatal rat models of chronic PHT with pulmonary vascular remodeling (chronic hypoxia, 0.13 FIO2, or 1 mg·kg–1·day–1 ip chronic bleomycin for 14 days from birth). Activity of the RhoA/ROCK pathway and ROCK expression were increased in hypoxia- and bleomycin-induced PHT. In both models, severe PHT [characterized by raised pulmonary vascular resistance (PVR) and impaired right ventricular (RV) performance] did not respond acutely to inhaled NO (20 ppm for 15 min) or to a single bolus of a NO donor, 3-morpholinosydnonimine hydrochloride (SIN-1; 2 µg/kg ip). In contrast, a single intraperitoneal bolus of either ROCK inhibitor (Y-27632 or fasudil) completely normalized PVR but had no acute effect on RV performance. ROCK-mediated vasoconstriction appears to play a key role in chronic PHT in our two neonatal rat models. Inhibitors of ROCK have potential as a testable therapy in neonates with PHT that is refractory to NO.
Y-27632; fasudil; two-dimensional echocardiography; pulse wave Doppler; SIN-1
This article has been cited by other articles:
|
|
 |
|
  P. Tourneux, N. Markham, G. Seedorf, V. Balasubramaniam, and S. H. Abman Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats Am J Physiol Lung Cell Mol Physiol, December 1, 2009; 297(6): L1103 - L1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Knock, V. A. Snetkov, Y. Shaifta, S. Drndarski, J. P.T. Ward, and P. I. Aaronson Role of src-family kinases in hypoxic vasoconstriction of rat pulmonary artery Cardiovasc Res, December 1, 2008; 80(3): 453 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Aytekin, S. A. A. Comhair, C. de la Motte, S. K. Bandyopadhyay, C. F. Farver, V. C. Hascall, S. C. Erzurum, and R. A. Dweik High levels of hyaluronan in idiopathic pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L789 - L799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L71 - L78. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
